Roche (RHHBY.US) announced that the liver cancer phase III clinical trial TALENTACE has met its primary endpoint.

According to the Wisdom Financial APP, on May 21st, Roche (RHHBY.US) announced that the Phase III TALENTACE study had reached its primary endpoint. This study evaluated the efficacy and safety of atezolizumab, bevacizumab, and on-demand transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.